OneSource Specialty Pharma Limited has released its audited financial results for the quarter and financial year ended March 31, 2026. The company reported consolidated revenue of Rs. 14,215.90 million for the fiscal year. Additionally, the Board has approved the appointment of B S R & Co LLP as the new statutory auditor for a five-year term, succeeding Deloitte Haskins & Sells, effective from the conclusion of the 19th Annual General Meeting.
Financial Performance Overview
For the financial year ended March 31, 2026, OneSource Specialty Pharma Limited achieved a consolidated revenue from operations of Rs. 14,215.90 million. On a standalone basis, the company recorded annual revenue of Rs. 14,053.81 million with a standalone net profit of Rs. 212.10 million. The company continues to focus on its Contract Development and Manufacturing Organization (CDMO) business, which remains its primary reportable segment.
Strategic Leadership in Audit
In a significant move for corporate governance, the company has appointed B S R & Co LLP as the new statutory auditor. The appointment is for a term of five consecutive years, starting from the conclusion of the 19th Annual General Meeting and extending until the conclusion of the 24th Annual General Meeting. This transition follows the completion of the tenure of Deloitte Haskins & Sells, who served as the outgoing statutory auditors.
Operational Highlights
The company maintains a strong focus on its core business, which involves the development and manufacturing of pharmaceutical products and life sciences services. The Board confirmed that the audited financial results reflect an unmodified opinion from the auditors. All financial statements have been prepared in accordance with the Indian Accounting Standards, ensuring full transparency regarding the company’s consolidated financial position and ongoing business operations.
Source: BSE
